Regeneron Pharmaceuticals (REGN)
Health Care5 articles
Market Mood
Stocks Moving Premarket: Regeneron, Dominion Energy, Macy's
Premarket trading has seen significant movements for several stocks, including Regeneron, Dominion Energy, and Macy's. Key players in this market include Regeneron Pharmaceuticals, which has recently been the subject of speculation regarding their pipeline. The trading volume and price actions are indicative of investor sentiment ahead of the market open. Understanding these premarket shifts can provide insights into overall market trends and potential impacts on trading for the day.
Read More
Regeneron (REGN) Stock Drops After Melanoma Drug Trial Failure
Regeneron Pharmaceuticals (REGN) recently reported that its key melanoma drug trial did not achieve the desired outcomes compared to Merck’s Keytruda. This failure is significant as it raises concerns about the effectiveness of Regeneron's treatments in a competitive oncology market. Following the announcement, Regeneron's stock price declined, impacting investor sentiment negatively. The precise percentage drop in stock value was not disclosed, but market reactions generally reflect uncertainty surrounding the company's future drug development prospects.
Read More
Regeneron (REGN) First-Quarter Earnings Show 19% Revenue Growth
Regeneron Pharmaceuticals (REGN) posted first-quarter revenue of $3.6 billion, a 19% increase year-over-year, surpassing analysts' expectations of $3.48 billion. Despite a 10% drop in Eylea sales to $941 million, Libtayo sales surged 54% to $438 million, and Dupixent sales reached $1.6 billion, up 36%. The company also initiated a new $3 billion share repurchase program following an $803 million buyback in Q1. Additionally, the FDA granted accelerated approval for Otarmeni, a gene therapy for hearing loss, further enhancing Regeneron's market potential.
Read More
Regeneron (REGN) Offers Otarmeni Gene Therapy Free in U.S.
Regeneron Pharmaceuticals (REGN) announced its newly approved gene therapy, Otarmeni, will be offered for free in the U.S. while pricing in other countries is still undecided. CEO Leonard Schleifer indicated they are determining a fair price internationally. In clinical trials, 80% of participants saw hearing improvements, with estimates suggesting around 50 babies born annually in the U.S. with the condition. Analysts from Piper Sandler project peak sales of $130 million, emphasizing the limited financial impact due to the condition's rarity.
Read More
Regeneron (REGN) drug pricing deal lowers costs, offers free therapy
Regeneron (REGN) agreed to lower U.S. drug prices as part of a deal with President Trump, allowing for the first hearing-loss gene therapy to be offered for free to eligible U.S. patients following FDA approval. This agreement is part of a broader initiative involving 17 deals with pharmaceutical companies aimed at aligning U.S. drug prices with those in other developed nations. Regeneron's gene therapy, Otarmeni, has been projected to achieve peak sales of $130 million, offering significant potential market impact. The deal also includes a three-year exemption from tariffs on pharmaceutical products, which may influence pricing strategies.
Read More